Cannabinoids Clinical Trials Cultivation DEA 
The Cannigma
JUNE 14, 2021
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.
Veriheal
APRIL 11, 2022
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA). We could potentially develop north of 11,000 drugs that are cannabinoid-based. Fortunately, the U.S. Is the future exciting? Absolutely.” The post New U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
AUGUST 8, 2020
In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system. This new bill allows broad hemp cultivation.
Cannabis Law Report
JUNE 4, 2021
We support the Hemp Roundtable’s statements on psychoactive hemp and that it should be regulated separately from hemp, CBD, CBG and other non-psychoactive or non-intoxicating cannabinoids. Delta 8-THC is a psychoactive cannabinoid, just like Delta 9-THC, and legislators should regulate it as such.
Cannabis Law Report
APRIL 1, 2019
The Tobacco Authority of Thailand, or TOAT, is one of two governmental entities that has looked to capitalize on the sale of cannabinoids as soon as it received approval from the Food and Drug Administration, or FDA. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.
SpeedWeed
MARCH 28, 2021
CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? It was also unique because it used whole-plant cannabis, rather than single-molecule extracts or synthetic pharmaceutical cannabinoids. .
NORML
SEPTEMBER 20, 2019
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials.
Expert insights. Personalized for you.
133 
Let's personalize your content